ArticleAnnals of medicine2025
Association of follicle-stimulating hormone with dyslipidaemia in men with obstructive sleep apnoea.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeObstructive sleep apnoea (OSA) is associated with both abnormal hormone secretion and dyslipidaemia. Follicle-stimulating hormone (FSH) can induce postmenopausal dyslipidaemia. This study aimed to explore the relationship between FSH and dyslipidaemia among male OSA patients. PATIENTS AND
methodsA total of 257 subjects admitted to the Department of Otorhinolaryngology for uvulopalatopharyngoplasty between August 2020 and September 2022 were screened. Sleep breathing monitoring data, biochemical indicators, and physical measurements were collected. Spearman correlation tests were used to analyse the correlation between FSH and lipid levels. Logistic regression analysis was used to determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) for dyslipidaemia as assessed by the presence of hyper-TC, hyper-LDL-C, hypo-HDL-C and hyper-TG. The potential mediating role of FSH was estimated by the mediation analyses.
resultsA total of 194 patients with OSA were ultimately included. Participants with a higher FSH had more severe OSA, had higher TG levels and higher percentages of hyper-TG. A positive dose-response relationship was observed between FSH and OSA severity or TG (P for trend both < 0.05). There was a positive correlation between FSH and TG (
conclusionFSH was independently associated with hyper-TG and played a significant mediating role in the relationship between OSA and dyslipidaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.